coteauBeta Get App

TMDX

TransMedics Group, Inc.
$72.06
-0.47% Oct 22 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-50%-30%-10%+10%+30%Oct 2025Oct 2026Apr 202652w high $156.0052w low $60.10
TMDXSPY
1W
-5.8%
1M
-18.2%
3M
+1.3%
6M
-36.3%
YTD
-40.8%
1Y
-39.7%

Live chart

Loading live chart…

What they do

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Healthcare · Medical Devices

For information only · Important disclosures

Grades vs sector

Momentum
7th percentile in sector
F
12-1 return: -36.6%
Percentile within its GICS sector across the S&P 1500.
Growth
80th percentile in sector
A-
Revenue growth (YoY): +20.7%
Percentile within its GICS sector across the S&P 1500.
Value
18th percentile in sector
D
Forward E/P: 3.2% · EBITDA/EV: 4.1%
Percentile within its GICS sector across the S&P 1500.
Profitability
86th percentile in sector
A-
Profit margin: +22.7% · Return on equity: +36.3%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
PR Newswire · 18h ago

Key stats

Market value$2.5B
P/E (last 12 months)18.8
P/E (next 12 months, estimated)32.1
52-week range$60.10 – $156.00
Revenue growth (latest quarter vs a year ago)+20.7%
Dividend yieldNo dividend
Analyst consensusBuy (11)
Average analyst price target$98.73 (+37%)
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

Earnings

Next report: 2026-10-29 · after close · EPS est 0.29
24-1025-0225-0525-0725-1026-0226-0526-080.000.92
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-040.480.44-7.4%
2026-05-050.610.30-50.9%
2026-02-240.370.53+41.0%
2025-10-290.360.66+83.3%
2025-07-300.430.92+114.8%
2025-05-080.240.70+190.1%
2025-02-270.150.19+25.3%
2024-10-280.320.12-62.3%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$189.9M+20.7%
2026-03-31$173.9M–
2025-12-31$160.8M–
2025-09-30$143.8M–
2025-06-30$157.4M–
Rating changes
Reiterated
2026-10-13 · Canaccord Genuity reiterated Buy on TMDX
Initiated
2026-10-07 · Barclays started covering TMDX at Overweight
Reiterated
2026-09-08 · TD Cowen reiterated Buy on TMDX
Reiterated
2026-08-05 · UBS reiterated Neutral on TMDX
Reiterated
2026-08-05 · Piper Sandler reiterated Overweight on TMDX
Reiterated
2026-08-03 · Needham reiterated Buy on TMDX

Third-party analyst actions, not Coteau's views. All rating changes

Insider trades
Weill David
Director · 2026-09-11
Buy
$109.1K
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:29:24 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026